[1]陈玲玲,徐 伟,尚波波,等.国家谈判药品可获得性研究——基于苏州市公立医院采购数据的实证分析[J].卫生经济研究,2020,(12):17-20.
　CHEN Ling-ling,XU Wei,SHANG Bo-bo,et al.Research on the Availability of National Negotiated Drugs——An Empirical Analysis Based on the Purchasing Data of Public Hospitals in Suzhou[J].Journal Press of Health Economics Research,2020,(12):17-20.
点击复制

国家谈判药品可获得性研究—
—基于苏州市公立医院采购数据的实证分析
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
期数:
2020年12期
页码:
17-20
栏目:
专题研究
出版日期:
2020-12-01

文章信息/Info

Title:
Research on the Availability of National Negotiated Drugs
——An Empirical Analysis Based on the Purchasing Data of Public Hospitals in Suzhou
作者:
陈玲玲1; 徐 伟1; 尚波波1; 刘朝一1; 何仁鑫1; 刘海娇1
1.中国药科大学国际医药商学院，江苏 南京 211198
Author(s):
CHEN Ling-ling; XU Wei; SHANG Bo-bo; LIU Chao-yi; HE Ren-xin; LIU Hai-jiao
International Business School, China Pharmaceutical University, Nanjing Jiangsu 211198,China
关键词:
国家谈判药品; 可获得性; 苏州市; 公立医院
Keywords:
national negotiation drugs;  availability;  Suzhou;  public hospital
分类号:
R19；F840.684
文献标志码:
A
摘要:
利用苏州市公立医院国家谈判药品的采购数据，对国家采购药品的可获得性进行实证研究，并分析影响可获得性的因素。结果显示，国家谈判药品落地后，药品总体可获得性提高，但具体品种的可获得性普遍较低；影响可获得性的因素有政策、适应症的发病率、存在同类适应症药品、医院的医疗水平和药品日均费用等，其中政策影响较为突出。对此建议：优化医保支付方式，鼓励药品的替代使用；增加社会药房供应渠道，分担医院使用压力。
Abstract:
Based on the national negotiated drugs procurement data of public hospitals in Suzhou, this paper makes an empirical study on the availability of national negotiated drugs,and analyzes the factors that affect the availability.The results show that after the implementation of national negotiation drugs,the overall availability of drugs is improved,but the availability of specific varieties is generally low.The factors affecting the availability are policy,incidence of indications,existence of similar indication drugs,the medical level of hospitals and the average daily cost of drugs, among which the policy influence is more prominent.There are some suggestions:optimize the health insurance payment, encourage the alternative use of drugs,increase the supply channels of community pharmacies, and share the pressure of hospital use.

参考文献/References:

[1] 管晓东,史录文.基于WHO/HAI标准调查法的我国基本药物可及性评价方法研究[J].中国药房，2013（24）：2212-2215.
[2] 廖彬池，胡明，周乃彤，等.基本药物可及性评价指标体系研究[J].中国药房，2016，27（18）：2449-2451.
[3] 张瑜，李歆.基于WHO/HAI标准调查方法的南京市基本药物可获得性及可负担性调查分析[J].中国药房，2015，26（30）：4188-4192.
[4] 陈逸凡.医保谈判药品的社会药房使用渠道分析[J].中国药物评价，2018，35（1）：66-70.
[5] 孙可欣，郑荣寿，张思维，等.2015年中国分地区恶性肿瘤发病和死亡分析[J].中国肿瘤，2019，28（1）：1-11.
[6] 梁冰，王前强，陈凤磊，等.国家谈判药品对综合医院医保管理的影响及对策[J].卫生经济研究，2020（5）：42-44,49.
[7] 陈庆锋，康洽福，丁榕芳，等. 医保谈判药品纳入特药药房统筹结算可行性研究——基于福建省省本级医保谈判药品管理实践[J].中国医疗保险，2019（4）：51-56.
[8] 黄广振，李岿.徐州市特药管理工作的实践和探索[J].中国医疗保险，2018（7）：42-45.

相似文献/References:

[1]路 云,张闪闪,李世勇.江苏省基本药物制度实施效果评价与思考[J].卫生经济研究,2017,(10):45.
[2]刘 昉,李翠翠,马 健,等.基层用药公平可及性评价研究[J].卫生经济研究,2018,(04):46.
[3]吴玉霞,徐 伟,蔡功杰,等.基本药物可获得性影响因素研究——基于25省监测点数据的实证分析[J].卫生经济研究,2018,(12):37.
　WU Yu-xia,XU Wei,CAI Gong-jie,et al.Study on the Factors Affecting the Availability of Essential Drugs——An Empirical Analysis Based on Data from 25 Provinces[J].Journal Press of Health Economics Research,2018,(12):37.
[4]李孟林,徐 伟,杜雯雯,等.我国上市专利药品可获得性实证研究[J].卫生经济研究,2019,(12):59.
　LI Meng-lin,XU Wei,DU Wen-wen,et al.Empirical Study on the Availability of Patented Drugs in China[J].Journal Press of Health Economics Research,2019,(12):59.
[5]梁 冰,王前强,陈凤磊,等.国家谈判药品对综合医院医保管理的影响及对策[J].卫生经济研究,2020,(05):42.
　LIANG Bing,WANG Qian-qiang,CHEN Feng-lei,et al.Impact of National Negotiation Drugs on Medical Insurance Management in General Hospitals and Countermeasures[J].Journal Press of Health Economics Research,2020,(12):42.
[6]严 晶,张 燕.DRG付费下国家谈判药品政策落地的实践[J].卫生经济研究,2021,38(12):20.
　YAN Jing,ZHANG Yan.Practice of National Negotiated Drug Policy Implementation under DRG Payment[J].Journal Press of Health Economics Research,2021,38(12):20.
[7]张钰婉,谈在祥,卢亚娟.国家谈判药品“双通道”模式实施现状及优化建议——以S市为例[J].卫生经济研究,2022,39(4):15.
　ZHANG Yu-wan,TAN Zai-xiang,LU Ya-juan.Implementation Status and Optimized Suggestions of the "Dual-Channel" Model for National Negotiation Drugs——Taking S City as An Example[J].Journal Press of Health Economics Research,2022,39(12):15.
[8]曹 庄,李赛赛,曹人元,等.国家医保谈判药品落地情况研究——基于5市17种国谈抗癌药使用及报销数据的分析[J].卫生经济研究,2022,39(7):53.
　CAO Zhuang,LI Saisai,CAO Renyuan,et al.Research on the Accessibility of National Medical Insurance Negotiation Drugs ——An Analysis Based on the Usage and Reimbursement Data of 17 National Negotiated Anticancer Drugs in Five Cities[J].Journal Press of Health Economics Research,2022,39(12):53.
[9]王宁锋,李雪竹,张 慧.国谈药单行支付政策研究[J].卫生经济研究,2024,41(06):16.
　WANG Ningfeng,LI Xuezhu,ZHANG Hui.Study on One-way Payment Policy for the State-negotiated Drugs[J].Journal Press of Health Economics Research,2024,41(12):16.
[10]郭孟子,李紫航,陈艺璇,等.“三医”协同视角下国谈药“双通道”高质量发展研究[J].卫生经济研究,2024,41(08):4.
　GUO Mengzi,LI Zihang,CHEN Yixuan,et al.Study on the High-quality Development of the "Dual channel" of National Negotiated Drugs from the Perspective of "Three Medical" Synergy[J].Journal Press of Health Economics Research,2024,41(12):4.
[11]罗 银,吴雨欣,杨赐然,等.湖北省国谈药可获得性研究 ——基于公立医院和零售药店的数据分析[J].卫生经济研究,2024,41(08):8.
　LUO Yin,WU Yuxin,YANG Ciran,et al.Study on the Availability of National Negotiated Drugs in Hubei Province ——Based on the Data Analysis of Public Hospitals and Retail Pharmacies[J].Journal Press of Health Economics Research,2024,41(12):8.

更新日期/Last Update: 2020-12-01